REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Inclusion Criteria

• •1. Patients with diagnosis of extensive-stage Small Cell Lung Cancer (ES-SCLC).
• •2. Patients entered, at least 24 months prior to the study inclusion, the D419QR00007 Early Access Programme (CASPIAN EAP) implemented in Italy.
• •3. Adult patients (aged ≥ 18 years) at the time of inclusion in the CASPIAN EAP.
• •4. Patients having performed at least one administration of durvalumab treatment in the CASPIAN EAP.
• •5. Patients (or their legally acceptable representatives) who have signed the subject informed consent and privacy form, if applicable.